Nephrology Month in Review: January 2024
Our January 2024 month-in-review spotlights some of our top coverage in nephrology, ranging from FDA news to clinical trial data and research about approaches to improving renal health.
Source: hcplive.com
Event Report System News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Event Report System. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Event Report System Today - Breaking & Trending Today
Endocrinology Month in Review: January 2024
This endocrinology month in review spotlights FDA news, a pair of studies examining cardiovascular and renal risk reduction in type 2 diabetes, results from a subtrial examining testosterone’s effect on fracture risk, and 4 new episodes of diabetes dialgoue
Source: hcplive.com
Amgen Osteoporosis Drug Prolia Is Hit With FDA's Strictest Warning
The FDA said Amgen’s Prolia may lead to low levels of calcium, or hypocalcemia. The osteoporosis drug’s black box warning follows an FDA review of Centers for Medicare & Medicaid Services studies that found Prolia led to a significant increase in the risk of severe hypocalcemia compared to treatment with an older class of medicines.
Source: medcitynews.com
FDA Adds Boxed Warning to Denosumab (Prolia) for Severe Hypocalcemia
On January 19, 2024, the FDA announced the addition of a Boxed Warning to the labeling of denosumab (Prolia), citing evidence of an increased risk of severe hypocalcemia in patients with chronic kidney disease.
Source: hcplive.com